Committee Name: Health Technology Expert Review Panel (HTERP)
Dr. Jean-Eric Tarride — Conflict of Interest Disclosure (Dated February 2020)
During the past three years, Dr. Jean-Eric Tarride has previously been engaged by Allergan to lead educational workshops on health technology assessment. He has received research funding or grants from AstraZeneca, Amgen, CSL Behring, Novo Nordisk, Sage, Assurex/Myriad, and Edwards Lifesciences for various health technology assessments, economic evaluations, and burden-of-illness studies.

Dr. Tarride has also been compensated by AstraZeneca, Pfizer Inc., GlaxoSmithKline, Edwards Lifesciences, Roche, Evidera, the European Commission Initiative on Breast Cancer, Amgen, PCDI Canada, Novartis, Bayer, Analytica Laser International, Lilly, Merck, Flatiron for providing advice around overall methodology and health technology assessment/management methods, and issues pertaining to market access including study design, cost-effectiveness, and reimbursement issues for various products across therapeutic areas.